Literature DB >> 7489990

Hepatoma cell-specific expression of a retrovirally transferred gene is achieved by alpha-fetoprotein but not insulinlike growth factor II regulatory sequences.

P Arbuthnot1, M P Bralet, H Thomassin, J L Danan, C Bréchot, N Ferry.   

Abstract

To target gene expression to malignant hepatic cells, we have constructed recombinant retroviral vectors containing a reporter gene encoding nuclear beta-galactosidase (nls-LacZ) under transcriptional control of regulatory sequences from the rat alpha-fetoprotein (AFP) or human insulinlike growth factor II (IGFII) genes. The AFP and IGFII P3 promoters activate transcription during fetal development and are often reactivated in hepatocellular carcinoma (HCC). Infection of several cultured cell types with the retroviral vector containing the IGFII P3 sequence resulted in expression of the reporter gene in all cell lines tested, including those that do not produce IGFII. In contrast, selective expression was achieved by vectors containing the AFP transcriptional regulatory sequence. Nuclear beta-galactosidase activity was detectable in cells from lines that produce AFP, and not in cells that do not express the AFP gene. In most infected cell lines, retroviral RNA synthesis from the 5' LTR was inhibited, and deletion of the retroviral LTR enhancer did not change expression from either the IGFII P3-nls-LacZ or the AFP-nls-LacZ cassettes. After treatment of cells with 12-O-tetradecanoylphorbol-13-acetate and epidermal growth factor (EGF), the decrease in concentrations of endogenous AFP messenger RNA (mRNA) and nls-LacZ mRNA transcribed from the transferred AFP regulatory sequence were similar. In the context of an integrated provirus, the AFP transcriptional regulatory sequence is therefore subject to similar regulatory control as that of the endogenous gene. These data show that the AFP sequence, and not the IGFII P3 promoter we used, is suitable for targeting gene expression to malignant hepatic cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489990

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  4 in total

1.  Construction of a regulable gene therapy vector targeting for hepatocellular carcinoma.

Authors:  Shao-Ying Lu; Yan-Fang Sui; Zeng-Shan Li; Cheng-En Pan; Jing Ye; Wen-Yong Wang
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

2.  Obese gene expression at in vivo levels by fat pads derived from s.c. implanted 3T3-F442A preadipocytes.

Authors:  S Mandrup; T M Loftus; O A MacDougald; F P Kuhajda; M D Lane
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

Review 3.  Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma.

Authors:  Patrick Arbuthnot; Liam-Jed Thompson
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

4.  Targeting Gene-Viro-Therapy with AFP driving Apoptin gene shows potent antitumor effect in hepatocarcinoma.

Authors:  Kang-Jian Zhang; Jing Qian; Shi-Bing Wang; Yi Yang
Journal:  J Biomed Sci       Date:  2012-02-09       Impact factor: 8.410

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.